ARC Launches ‘ARC Landing Boston’ Healthtech Accelerator with Massachusetts Governor Maura Healey

Why It Matters

The accelerator accelerates U.S. market entry for foreign healthtech firms, driving high‑skill job creation and attracting billions of international capital to Massachusetts, reinforcing its status as a global biotech hub.

Key Takeaways

• ARC Landing Boston offers soft‑landing for global healthtech firms
• Six inaugural startups have raised $85M collectively
• Program links startups to Massachusetts clinical sites and investors
• ARC’s network includes 130+ startups valued over $6.7B
• Expected to generate high‑skill jobs and attract international capital

Pulse Analysis

The United States remains the most lucrative but also most regulated market for health technology. Foreign innovators often stumble on FDA pathways, reimbursement models, and fragmented provider networks. ARC, the innovation arm of Israel’s Sheba Medical Center, has responded by launching ARC Landing Boston, a soft‑landing accelerator built in partnership with Governor Maura Healey’s administration. By embedding startups directly within Boston’s clinical ecosystem, the program promises to streamline regulatory navigation, accelerate clinical validation, and connect entrepreneurs with the venture capital that fuels U.S. growth.

The inaugural cohort comprises six high‑growth companies tackling distinct clinical challenges. XEOS brings real‑time molecular imaging to the operating room, potentially reshaping cancer surgery. UltraSight’s AI‑driven cardiac ultrasound enables non‑specialists to acquire diagnostic scans, expanding access to heart care. FeelBetter applies artificial intelligence to medication management at scale, while Modulight pursues optogenetic therapies for severe neurological disorders. CustoMED offers AI‑enhanced, 3‑D orthopedic planning, and Nuri Braintech develops a brain‑computer interface for PTSD. Together, these startups have already raised $85 million, underscoring strong investor confidence.

Massachusetts stands to reap substantial economic benefits as ARC Landing Boston channels international capital into the state. The accelerator is projected to create high‑skill jobs in biotech, data science, and regulatory affairs, reinforcing Boston’s reputation as a global health‑innovation hub. By linking foreign founders with local hospitals, investors, and research institutions, the program accelerates technology transfer and shortens time‑to‑market for breakthrough therapies. If the cohort’s products achieve commercial success, the ripple effect could attract further foreign startups, cementing the Commonwealth’s role as the premier landing pad for healthtech worldwide.